UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
S.Z. Usmani(Levine Cancer Institute), Sundar Jagannath(Mount Sinai Hospital), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), Parameswaran Hari(Medical College of Wisconsin), Lida Pacaud(Centro de Investigación del Cáncer), Yukang Lin(Fred Hutch Cancer Center), Arnob Banerjee(Johnson & Johnson (United States)), Xiaoxiao Wu(Guangzhou Institute of Advanced Technology), Thomas G. Martin(University of California San Francisco Medical Center), Jackson Cc(Janssen (United States)), J. G. Berdeja(Sarah Cannon), William Deraedt(Janssen (Belgium)), Muhammad Akram(Unknown), T.‐J. Yeh(Janssen (United States)), Andrzej Jakubowiak(University of Chicago), AD Cohen(University of Pennsylvania), Alicia J. Allred(Queen's University Belfast), M Agha(UPMC Hillman Cancer Center), Yunsi Olyslager(Janssen (Belgium))
Cited by 21
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Awareness and current knowledge of breast cancer
|Biological Research|2017|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k